Flamel and Merck join for formulation of therapeutic proteins

Under the terms of the agreement, Merck Serono will make an upfront payment of E2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund R&D efforts to be performed at Flamel. Financial terms of a license agreement up through potential commercialization of this formulation have been agreed between the parties.

Bernhard Kirschbaum, head of research at Merck Serono, said: “We are delighted to enter into this partnership with Flamel, as it gives Merck Serono access to a technology that may further improve the therapeutic potential of compounds in our portfolio.”